ORLANDO, FL, USA (UroToday.com) - An initial Phase I trial of intravesical docetaxel treatment for patients with non-muscle-invasive bladder cancer demonstrated impressive initial response rates, but disappointing durability.
Your session will expire in 8 hours requiring you to log in each day to view content.